Rapid Tranquilization of Severely Agitated Patients With Schizophrenia Spectrum Disorders

被引:27
|
作者
Walther, Sebastian [1 ]
Moggi, Franz [1 ,2 ]
Horn, Helge [1 ]
Moskvitin, Konstantin [1 ]
Abderhalden, Christoph [1 ,3 ]
Maier, Nadja [1 ]
Strik, Werner [1 ]
Mueller, Thomas J. [1 ]
机构
[1] Univ Hosp Psychiat, CH-3000 Bern 10, Switzerland
[2] Univ Fribourg, Dept Psychol, CH-1700 Fribourg, Switzerland
[3] Univ Hosp Psychiat, Nursing & Social Educ Res Unit, CH-3000 Bern 10, Switzerland
关键词
aggressive behavior; agitation; schizophrenia; rapid tranquilization; haloperidol; risperidone; olanzapine; HALOPERIDOL PLUS PROMETHAZINE; INTRAMUSCULAR HALOPERIDOL; PSYCHOTIC AGITATION; ORAL RISPERIDONE; OLANZAPINE; VIOLENT; TRIAL; AGGRESSION; MANAGEMENT; LORAZEPAM;
D O I
10.1097/JCP.0000000000000050
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Agitation is a major problem in acute schizophrenia. Only a few studies have tested antipsychotic agents in severely agitated patients, mainly because of legal issues. Furthermore, most studies were limited to the first 24 hours. We aimed to investigate the efficacy of oral haloperidol, risperidone, and olanzapine in reducing psychotic agitation in severely agitated patients with schizophrenia or schizophreniform or schizoaffective disorder over 96 hours using a prospective, randomized, rater-blinded, controlled design within a naturalistic treatment regimen. Methods: In total, 43 severely agitated patients at acute care psychiatric units were enrolled. Participants were randomly assigned to receive either daily haloperidol 15 mg, olanzapine 20 mg, or risperidone 2 to 6 mg over 5 days. Positive and Negative Syndrome Scale psychotic agitation subscale score was the primary outcome variable. A mixed-model analysis was applied. Results: All drugs were effective for rapid tranquilization within 2 hours. Over 5 days, the course differed between agents (P < 0.001), but none was superior. Dropouts occurred only in the risperidone and olanzapine groups. Men responded better to treatment than did women during the initial 2 hours (P = 0.046) as well as over the 5-day course (P < 0.001). No difference between drug groups was observed regarding diazepam or biperiden use. Conclusions: Oral haloperidol, risperidone, and olanzapine seem to be suitable for treating acute severe psychotic agitation in schizophrenia spectrum disorders. Response to oral antipsychotics demonstrated a gender effect with poorer outcome in women throughout the study.
引用
收藏
页码:124 / 128
页数:5
相关论文
共 50 条
  • [41] Factors associated with drug attitude in patients with schizophrenia spectrum disorders
    Harber, Lillian
    Takeuchi, Hiroyoshi
    Borlido, Carol
    Hamidian, Reza
    Remington, Gary
    SCHIZOPHRENIA RESEARCH, 2017, 188 : 185 - 186
  • [42] Neurocognitive Outcomes in the Treatment of Early-Onset Schizophrenia Spectrum Disorders Study
    Frazier, Jean A.
    Giuliano, Anthony J.
    Johnson, Jacqueline L.
    Yakutis, Lauren
    Youngstrom, Eric A.
    Breiger, David
    Sikich, Linmarie
    Findling, Robert L.
    McClellan, Jon
    Hamer, Robert M.
    Vitiello, Benedetto
    Lieberman, Jeffrey A.
    Hooper, Stephen R.
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2012, 51 (05) : 496 - 505
  • [43] Relationship of Cognition to Clinical Response in First-Episode Schizophrenia Spectrum Disorders
    Trampush, Joey W.
    Lencz, Todd
    DeRosse, Pamela
    John, Majnu
    Gallego, Juan A.
    Petrides, Georgios
    Hassoun, Youssef
    Zhang, Jian-Ping
    Addington, Jean
    Kellner, Charles H.
    Tohen, Mauricio
    Burdick, Katherine E.
    Goldberg, Terry E.
    Kane, John M.
    Robinson, Delbert G.
    Malhotra, Anil K.
    SCHIZOPHRENIA BULLETIN, 2015, 41 (06) : 1237 - 1247
  • [44] Transition from Ziprasidone IM to Oral Formulation in Agitated Patients with Acute Exacerbation of Schizophrenia: An Open Trial
    Mautone, A.
    Scarone, S.
    PHARMACOPSYCHIATRY, 2011, 44 (05) : 173 - 178
  • [45] Acute Antipsychotic Treatment of Children and Adolescents With Schizophrenia-Spectrum Disorders: A Systematic Review and Network Meta-Analysis
    Pagsberg, Anne Katrine
    Tarp, Simon
    Glintborg, Dorte
    Stenstrom, Anne Dorte
    Fink-Jensen, Anders
    Correll, Christoph Ulrich
    Christensen, Robin
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2017, 56 (03) : 191 - 202
  • [46] Psychometric Characteristics and Sociodemographic Adaptation of the Corrigan Agitated Behavior Scale in Patients With Severe Mental Disorders
    Garrote-Camara, Maria Elena
    Santolalla-Arnedo, Ivan
    Ruiz de Vinaspre-Hernandez, Regina
    Gea-Caballero, Vicente
    Sufrate-Sorzano, Teresa
    del Pozo-Herce, Pablo
    Garrido-Garcia, Rebeca
    Rubinat-Arnaldo, Esther
    Vela, Raul Juarez
    FRONTIERS IN PSYCHOLOGY, 2021, 12
  • [47] Treatment With Acamprosate in Patients With Schizophrenia Spectrum Disorders and Comorbid Alcohol Dependence
    Ralevski, Elizabeth
    O'Brien, Erin
    Jane, J. Serrita
    Dwan, Rita
    Dean, Erica
    Edens, Ellen
    Arnaout, Bachaar
    Keegan, Kathryn
    Drew, Shannon
    Petrakis, Ismene
    JOURNAL OF DUAL DIAGNOSIS, 2011, 7 (1-2) : 64 - 73
  • [48] Increased Risk of Parkinson's Disease in Patients With Schizophrenia Spectrum Disorders
    Kuusimaki, Tomi
    Al-Abdulrasul, Haidar
    Kurki, Samu
    Hietala, Jarmo
    Hartikainen, Sirpa
    Koponen, Marjaana
    Tolppanen, Anna-Maija
    Kaasinen, Valtteri
    MOVEMENT DISORDERS, 2021, 36 (06) : 1353 - 1361
  • [49] Duration mismatch negativity in biological relatives of patients with schizophrenia spectrum disorders
    Michie, PT
    Innes-Brown, H
    Todd, J
    Jablensky, AV
    BIOLOGICAL PSYCHIATRY, 2002, 52 (07) : 749 - 758
  • [50] Association of clinical symptoms and cardiometabolic dysregulations in patients with schizophrenia spectrum disorders
    Zhao, Chenxu
    Habtewold, Tesfa Dejenie
    Naderi, Elnaz
    Liemburg, Edith J.
    Bruggeman, Richard
    Alizadeh, Behrooz Z.
    EUROPEAN PSYCHIATRY, 2023, 67 (01)